Chronic Myeloid Leukemia (CML) remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level and has been used by researchers to develop a variety of therapies and therapeutic assessment methods. This concise, readable guide assembles and synthesizes the latest developments and trends in the treatment of CML and provides an authoritative and convenient summary of the latest progress in imatinib trials, the molecular monitoring of CML responses, and the engineering of new therapies to overcome resistance and improve patient care.
Providing critical insight and exploration of models that will enhance the cancer community at large, this source:
stands as the only source to focus on post-Gleevec developments in CML therapeutics
collects information from the forefront of the fieldhelping busy clinicians make informed management decisions
supplies critical research from recognized opinion leaders on the topic
provides an overview of the current status of new transplant modalities
contains a vivid selection of color photographs
| Preface |
|
iii | |
| Contributors |
|
vii | |
|
BCR-ABL as a Molecular Target |
|
|
1 | (12) |
|
|
|
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia |
|
|
13 | (14) |
|
|
|
|
|
Where Are We Today with Imatinib Therapy? |
|
|
27 | (18) |
|
|
|
Monitoring Chronic Myeloid Leukemia in 2006 |
|
|
45 | (14) |
|
|
|
|
|
|
|
Dasatinib: A Dual ABL and SRC Inhibitor |
|
|
59 | (10) |
|
|
|
|
|
|
|
Nilotinib (AMN107) for the Treatment of Chronic Myelogenous Leukemia |
|
|
69 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
79 | (16) |
|
|
|
|
|
Immunotherapy of Chronic Myeloid Leukemia |
|
|
95 | (14) |
|
|
|
|
|
Molecular Targets Other than Bcr-Abl: How to Incorporate Them into the CML Therapy? |
|
|
109 | (16) |
|
|
|
|
|
Blastic Transformation of Chronic Myelogenous Leukemia: Does BCR-ABL Orchestrate Disease Progression? |
|
|
125 | (24) |
|
|
|
|
|
Early Intensification of Therapy: The Role of High-Dose Imatinib and Imatinib-Based Combinations |
|
|
149 | (8) |
|
|
|
|
|
|
|
|
| Index |
|
157 | |
JORGE CORTES is Deputy Chair, Department of Leukemia, and Professor of Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas. A member of several medical societies, Dr. Cortes has served as a lecturer and the author/co-author of over 300 medical publications and abstracts and has greatly contributed to the search for effective treatments for leukemias. Dr. Cortes is the recipient of a variety of awards including the Merit Award (1995) from American Society of Clinical Oncology, the Upjohn Outstanding Research Award (1995) from M.D. Anderson Cancer Center, and was recently a Clinical Research Scholar for the Leukemia Lymphoma Society. Dr. Cortes is the recipient of the Faculty Scholar Award from M.D. Anderson (2003), and the Celgene Young Investigator Award (2005).
MICHAEL DEININGER is Scientific Director of the CML Basic Research Program and Assistant Professor, Center for Hematologic Malignancies, Oregon Health & Science University, Portland. Dr. Deininger is a member of the American Society of Hematology and the American Society of Clinical Oncology. He received the M.D. degree from the University of Wuerzburg, Germany, and the Ph.D. degree from Imperial College, London. He has published numerous research and scholarly articles in peer-reviewed journals, covering molecular and clinical aspects of CML, and serves as a peer reviewer for Blood, Nature Genetics, The Lancet, Cancer Research, and other professional journals. Dr. Deiningers honors include scholarships from the German Scholarship Foundation and the American Society of Hematology.
Biežāk uzdotie jautājumi par e-grāmatām